1. Home
  2. TYRA vs NFE Comparison

TYRA vs NFE Comparison

Compare TYRA & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • NFE
  • Stock Information
  • Founded
  • TYRA 2018
  • NFE 2014
  • Country
  • TYRA United States
  • NFE United States
  • Employees
  • TYRA N/A
  • NFE N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • NFE Oil/Gas Transmission
  • Sector
  • TYRA Health Care
  • NFE Utilities
  • Exchange
  • TYRA Nasdaq
  • NFE Nasdaq
  • Market Cap
  • TYRA 844.2M
  • NFE 773.2M
  • IPO Year
  • TYRA 2021
  • NFE 2019
  • Fundamental
  • Price
  • TYRA $22.01
  • NFE $1.18
  • Analyst Decision
  • TYRA Strong Buy
  • NFE Strong Buy
  • Analyst Count
  • TYRA 5
  • NFE 5
  • Target Price
  • TYRA $31.20
  • NFE $7.70
  • AVG Volume (30 Days)
  • TYRA 448.1K
  • NFE 20.7M
  • Earning Date
  • TYRA 11-05-2025
  • NFE 12-05-2025
  • Dividend Yield
  • TYRA N/A
  • NFE N/A
  • EPS Growth
  • TYRA N/A
  • NFE N/A
  • EPS
  • TYRA N/A
  • NFE N/A
  • Revenue
  • TYRA N/A
  • NFE $1,768,624,000.00
  • Revenue This Year
  • TYRA N/A
  • NFE N/A
  • Revenue Next Year
  • TYRA N/A
  • NFE $27.93
  • P/E Ratio
  • TYRA N/A
  • NFE N/A
  • Revenue Growth
  • TYRA N/A
  • NFE N/A
  • 52 Week Low
  • TYRA $6.42
  • NFE $0.98
  • 52 Week High
  • TYRA $22.68
  • NFE $16.66
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 83.81
  • NFE 42.68
  • Support Level
  • TYRA $14.84
  • NFE $1.06
  • Resistance Level
  • TYRA $22.68
  • NFE $1.60
  • Average True Range (ATR)
  • TYRA 1.57
  • NFE 0.17
  • MACD
  • TYRA 0.71
  • NFE 0.03
  • Stochastic Oscillator
  • TYRA 94.18
  • NFE 35.04

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

Share on Social Networks: